Need a specific person's email?
Browse Oncolytics Biotech Inc.'s employee directory (about 46 employees) and reveal verified emails free.
Oncolytics Biotech Inc.'s most common email format is First.Last@oncolyticsbiotech.com (ex. John.Doe@oncolyticsbiotech.com), used for 100% of oncolyticsbiotech.com addresses. Oncolytics Biotech Inc. uses 5 email patterns across 2 domains: oncolyticsbiotech.com and oncolytics.ca. Percentages are the share of addresses within each domain.
| Format | Example | Share of oncolyticsbiotech.com |
|---|---|---|
| First.Last@oncolyticsbiotech.comMost common | John.Doe@oncolyticsbiotech.com |
| Format | Example | Share of oncolytics.ca |
|---|---|---|
| FLast@oncolytics.caMost common | JDoe@oncolytics.ca | |
| FirstL@oncolytics.ca | JohnD@oncolytics.ca | |
| FirstLast@oncolytics.ca | JohnDoe@oncolytics.ca | |
| Last@oncolytics.ca | Doe@oncolytics.ca |
Browse Oncolytics Biotech Inc.'s employee directory (about 46 employees) and reveal verified emails free.
Biotechnology ResearchCalifornia, United States11-50 Employees
Oncolytics Biotech Inc. is a biotechnology research company based in San Diego, California, focused on oncology. It is developing pelareorep, an intravenously delivered immunotherapy designed to trigger both innate and adaptive immune responses while undermining tumor defenses, with the aim of enhancing the immune system's capacity to attack cancer and making tumors more responsive to diverse cancer treatments. This places the company within the field of cancer immunotherapy development. The company targets oncology researchers, clinicians, and patients seeking new immunotherapeutic options to complement existing therapies. In 2026, Oncolytics launched the randomized Phase 2 REO-033 trial evaluating pelareorep in ras-mutant MSS metastatic colorectal cancer.
Most common format
First.Last@oncolyticsbiotech.com
Example: John.Doe@oncolyticsbiotech.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.